Madrigal Pharmaceuticals, Inc. (MDGL)
Chart Events
Performance Outlook
| Previous Close | 74.55 |
| Open | 74.40 |
| Bid | 72.65 x 800 |
| Ask | 73.21 x 1400 |
| Day's Range | 70.76 - 74.40 |
| 52 Week Range | 52.33 - 105.93 |
| Volume | |
| Avg. Volume | 178,232 |
| Market Cap | 1.248B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.65 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 157.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MDGL
Related Research
- Madrigal Pharmaceuticals, Inc.Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.RatingFair ValueEconomic Moat7 days agoArgus Research
- GlobeNewswire
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports its second quarter 2022 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal,
- Benzinga
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. Consistent with the previous top-line data, the most frequently reported adverse event
- GlobeNewswire
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan and MRE, and liver enzymes, as well as multiple atherogenic lipidsIn NASH patients with well-compensated cirrhosis, resmetirom: was safe and well toleratedreduced liver fat, LDL-C, and other atherogenic lipidsreduced noninvasive measures of liver fibrosis and liver enzymesreduced liver volume by an
